171 related articles for article (PubMed ID: 15229634)
21. Severe clinical forms of cytochrome b-negative chronic granulomatous disease (X91-) in 3 brothers with a point mutation in the promoter region of CYBB.
Stasia MJ; Brion JP; Boutonnat J; Morel F
J Infect Dis; 2003 Nov; 188(10):1593-604. PubMed ID: 14624387
[TBL] [Abstract][Full Text] [Related]
22. Gamma-glutamylcysteine synthetase-based selection strategy for gene therapy of chronic granulomatous disease and graft-vs.-host disease.
Rappa G; Anzanello F; Alexeyev M; Fodstad O; Lorico A
Eur J Haematol; 2007 May; 78(5):440-8. PubMed ID: 17331133
[TBL] [Abstract][Full Text] [Related]
23. Chronic granulomatous disease: towards gene therapy.
Thrasher A; Segal A; Casimir C
Immunodeficiency; 1993; 4(1-4):327-33. PubMed ID: 8167728
[TBL] [Abstract][Full Text] [Related]
24. Development of a novel selective amplifier gene for controllable expansion of transduced hematopoietic cells.
Ito K; Ueda Y; Kokubun M; Urabe M; Inaba T; Mano H; Hamada H; Kitamura T; Mizoguchi H; Sakata T; Hasegawa M; Ozawa K
Blood; 1997 Nov; 90(10):3884-92. PubMed ID: 9354655
[TBL] [Abstract][Full Text] [Related]
25. Gene therapy of chronic granulomatous disease (CGD) by gene transfer into hematopoietic stem cells.
Zentilin L; Tafuro S; Serra C; Falaschi A; Giacca M
Ann Ist Super Sanita; 1998; 34(4):447-55. PubMed ID: 10234875
[TBL] [Abstract][Full Text] [Related]
26. [Statistical evaluation of chronic granulomatous disease in Japan and basic studies for gene therapy for CGD patients].
Nunoi H; Ishibashi F
Rinsho Byori; 1999 Jul; 47(7):658-64. PubMed ID: 10442045
[TBL] [Abstract][Full Text] [Related]
27. A G-CSF receptor-gyrase B fusion gene: A new type of molecular switch for expansion of genetically modified hematopoietic cells.
Kume A; Ito K; Ueda Y; Hasegawa M; Urabe M; Mano H; Ozawa K
Biochem Biophys Res Commun; 1999 Jun; 260(1):9-12. PubMed ID: 10381335
[TBL] [Abstract][Full Text] [Related]
28. Preselective gene therapy for Fabry disease.
Qin G; Takenaka T; Telsch K; Kelley L; Howard T; Levade T; Deans R; Howard BH; Malech HL; Brady RO; Medin JA
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3428-33. PubMed ID: 11248095
[TBL] [Abstract][Full Text] [Related]
29. A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X-linked CGD by selection for MDR1 expression.
Sokolic RA; Sekhsaria S; Sugimoto Y; Whiting-Theobald N; Linton GF; Li F; Gottesman MM; Malech HL
Blood; 1996 Jan; 87(1):42-50. PubMed ID: 8547675
[TBL] [Abstract][Full Text] [Related]
30. Gene therapy for chronic granulomatous disease.
Stein S; Siler U; Ott MG; Seger R; Grez M
Curr Opin Mol Ther; 2006 Oct; 8(5):415-22. PubMed ID: 17078383
[TBL] [Abstract][Full Text] [Related]
31. Genetic correction of X-linked chronic granulomatous disease with novel foamy virus vectors.
Chatziandreou I; Siapati EK; Vassilopoulos G
Exp Hematol; 2011 Jun; 39(6):643-52. PubMed ID: 21426924
[TBL] [Abstract][Full Text] [Related]
32. Progress toward effective gene therapy for chronic granulomatous disease.
Malech HL; Choi U; Brenner S
Jpn J Infect Dis; 2004 Oct; 57(5):S27-8. PubMed ID: 15507764
[TBL] [Abstract][Full Text] [Related]
33. Efficient engraftment of in utero transplanted mice with retrovirally transduced hematopoietic stem cells.
Rio P; Martinez-Palacio J; Ramirez A; Bueren JA; Segovia JC
Gene Ther; 2005 Feb; 12(4):358-63. PubMed ID: 15550924
[TBL] [Abstract][Full Text] [Related]
34. Deficiency of oncoretrovirally transduced hematopoietic stem cells and correction through ex vivo expansion.
Bryder D; Björgvinsdóttir H; Sasaki Y; Jacobsen SE
J Gene Med; 2005 Feb; 7(2):137-44. PubMed ID: 15538726
[TBL] [Abstract][Full Text] [Related]
35. A murine model of antimetabolite-based, submyeloablative conditioning for bone marrow transplantation: biologic insights and potential applications.
Goebel WS; Pech NK; Meyers JL; Srour EF; Yoder MC; Dinauer MC
Exp Hematol; 2004 Dec; 32(12):1255-64. PubMed ID: 15588950
[TBL] [Abstract][Full Text] [Related]
36. High-level reconstitution of respiratory burst activity in a human X-linked chronic granulomatous disease (X-CGD) cell line and correction of murine X-CGD bone marrow cells by retroviral-mediated gene transfer of human gp91phox.
Ding C; Kume A; Björgvinsdóttir H; Hawley RG; Pech N; Dinauer MC
Blood; 1996 Sep; 88(5):1834-40. PubMed ID: 8781441
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic stem cells expanded by fibroblast growth factor-1 are excellent targets for retrovirus-mediated gene delivery.
Crcareva A; Saito T; Kunisato A; Kumano K; Suzuki T; Sakata-Yanagimoto M; Kawazu M; Stojanovic A; Kurokawa M; Ogawa S; Hirai H; Chiba S
Exp Hematol; 2005 Dec; 33(12):1459-69. PubMed ID: 16338488
[TBL] [Abstract][Full Text] [Related]
38. Gene correction reduces cutaneous inflammation and granuloma formation in murine X-linked chronic granulomatous disease.
Goebel WS; Mark LA; Billings SD; Meyers JL; Pech N; Travers JB; Dinauer MC
J Invest Dermatol; 2005 Oct; 125(4):705-10. PubMed ID: 16185269
[TBL] [Abstract][Full Text] [Related]
39. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.
Ott MG; Schmidt M; Schwarzwaelder K; Stein S; Siler U; Koehl U; Glimm H; Kühlcke K; Schilz A; Kunkel H; Naundorf S; Brinkmann A; Deichmann A; Fischer M; Ball C; Pilz I; Dunbar C; Du Y; Jenkins NA; Copeland NG; Lüthi U; Hassan M; Thrasher AJ; Hoelzer D; von Kalle C; Seger R; Grez M
Nat Med; 2006 Apr; 12(4):401-9. PubMed ID: 16582916
[TBL] [Abstract][Full Text] [Related]
40. Retrovirally transduced bone marrow has a therapeutic effect on brain in the mouse model of mucopolysaccharidosis IIIB.
Zheng Y; Ryazantsev S; Ohmi K; Zhao HZ; Rozengurt N; Kohn DB; Neufeld EF
Mol Genet Metab; 2004 Aug; 82(4):286-95. PubMed ID: 15308126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
